Psychopathological and Cognitive Effects of Therapeutic Cannabinoids in Multiple Sclerosis: A Double-Blind, Placebo Controlled, Crossover Study

被引:70
作者
Aragona, Massimiliano [2 ]
Onesti, Emanuela [3 ]
Tomassini, Valentina [1 ]
Conte, Antonella [1 ]
Gupta, Shiva [4 ]
Gilio, Francesca [1 ]
Pantano, Patrizia [1 ]
Pozzilli, Carlo [1 ]
Inghilleri, Maurizio [1 ]
机构
[1] Univ Roma La Sapienza, Dept Neurol Sci, I-00185 Rome, Italy
[2] Univ Roma La Sapienza, Chair Philosophy Psychopathol, I-00185 Rome, Italy
[3] Neurol Ctr Latium, Div Neurol, Rome, Italy
[4] Westchester Cty Med Ctr, Dept Radiol, Valhalla, NY 10595 USA
关键词
cannabinoids; psychosis; anxiety; cognition; multiple sclerosis; CONTROLLED-TRIAL; CENTRAL PAIN; FOLLOW-UP; TERM; PSYCHOSIS; SCALE; SPASTICITY; MEDICINE; EFFICACY; SAFETY;
D O I
10.1097/WNF.0b013e3181633497
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: To study possible psychopathological symptoms and cognitive deficits, abuse induction, as well as general tolerability and effects on quality of life, fatigue and motor function in cannabis-naive patients with multiple sclerosis (MS) treated with a free-dose cannabis plant extract (Sativex). Methods: In an 8-week, randomized, double-blind, placebo-controlled, parallel group crossover trial, 17 cannabis-naive patients with MS were assessed at baseline and at the end of the cannabis and placebo phases of the trial (each of 3 weeks) by means of Symptom Checklist-90 Revised, Self-rating Anxiety Scale. Multiple Sclerosis Functional Composite (of which 1 dimension is the Paced Auditory Serial Additional Test that was used to evaluate cognition), Visual Analogue Scale on health-related quality of life, Multiple Sclerosis Impact Scale-29, and Fatigue Severity Scale. Results: Postplacebo versus postcannabinoid scores showed that no significant differences could be detected on all the variables under study. A significant positive correlation was found between Delta-9-tetrahydrocannabinol blood levels and scores at the General Symptomatic Index and at the "interpersonal sensitivity," "aggressive behaviour," and "paranoiac tendencies" subscales of the Symptom Checklist-90 Revised. No serious adverse events, abuse tendencies, or direct withdrawal symptoms were reported. Increased desire for Sativex with secondary depression was reported in 1 subject. Conclusions: Cannabinoid treatment did not induce psychopathology and did not impair cognition in cannabis-naive patients with MS. However, the positive correlation between blood levels of Delta-9-tetrahydrocannabinol and psychopathological scores suggests that at dosages higher than those used in therapeutic settings, interpersonal sensitivity, aggressiveness, and paranoiac features might arise, although greater statistical power would be necessary to confirm this finding.
引用
收藏
页码:41 / 47
页数:7
相关论文
共 43 条
[1]   Abuse, dependence, and epileptic seizures after zolpidem withdrawal: Review and case report [J].
Aragona, M .
CLINICAL NEUROPHARMACOLOGY, 2000, 23 (05) :281-283
[2]   Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects [J].
Arendt, Mikkel ;
Rosenberg, Raben ;
Fjordback, Lone ;
Brandholdt, Jack ;
Foldager, Leslie ;
Sher, Leo ;
Munk-Jorgensen, Povl .
PSYCHOLOGICAL MEDICINE, 2007, 37 (07) :935-945
[3]   Abuse, dependence, or withdrawal associated with tramadol [J].
Brinker, A ;
Bonnel, RA ;
Beitz, J .
AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (05) :881-881
[4]   Cannabis use in patients with multiple sclerosis [J].
Chong, M. S. ;
Wolff, K. ;
Wise, K. ;
Tanton, C. ;
Winstock, A. ;
Silber, E. .
MULTIPLE SCLEROSIS JOURNAL, 2006, 12 (05) :646-651
[5]   Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis [J].
Collin, C. ;
Davies, P. ;
Mutiboko, I. K. ;
Ratcliffe, S. .
EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 (03) :290-296
[6]   The perceived effects of smoked cannabis on patients with multiple sclerosis [J].
Consroe, P ;
Musty, R ;
Rein, J ;
Tillery, W ;
Pertwee, R .
EUROPEAN NEUROLOGY, 1997, 38 (01) :44-48
[7]   Cognitive and subjective dose-response effects of acute oral Δ9-tetrahydrocannabinol (THC) in infrequent cannabis users [J].
Curran, HV ;
Brignell, C ;
Fletcher, S ;
Middleton, P ;
Henry, J .
PSYCHOPHARMACOLOGY, 2002, 164 (01) :61-70
[8]   The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis [J].
D'Souza, DC ;
Perry, E ;
MacDougall, L ;
Ammerman, Y ;
Cooper, T ;
Wu, YT ;
Braley, G ;
Gueorguieva, R ;
Krystal, JH .
NEUROPSYCHOPHARMACOLOGY, 2004, 29 (08) :1558-1572
[9]   Comorbid cannabis use and panic disorder: short term and long term follow-up study [J].
Dannon, PN ;
Lowengrub, K ;
Amiaz, R ;
Grunhaus, L ;
Kotler, M .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2004, 19 (02) :97-101
[10]   Is cannabis use a contributory cause of psychosis? [J].
Degenhardt, Louisa ;
Hall, Wayne .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2006, 51 (09) :556-565